Strategic Partnerships Riverain's recent and ongoing partnerships with VIDA Diagnostics, Azra AI, CARPL.ai, Reveal Dx, and University Medical Center New Orleans indicate a strong channel strategy and a willingness to integrate with complementary AI and imaging platforms. Leverage these alliances to position ClearRead as a interoperable option that enhances partner ecosystems and expands reference opportunities.

Global Expansion The company expanded across eight countries in 2024 and added nearly 50 new customers, suggesting a scalable sales model and growing demand for AI-powered thoracic imaging solutions. Target international radiology groups, tertiary referral centers, and health systems with multi-site networks to replicate this growth.

Regulatory Momentum Recent Health Canada approval for ClearRead CT CAC demonstrates regulatory progress and international credibility. Pursue opportunities in markets with similar regulatory pathways (Canada, Europe, other APAC regions) and emphasize compliance and accelerated adoption for imaging analytics.

Clinical Value Narrative ClearRead’s ability to improve detection and reduce radiologist workload addresses high-demand pain points in radiology departments facing staffing constraints and rising imaging volumes. Emphasize efficiency, reading throughput, and early disease detection in sales conversations with radiology directors and hospital administrators.

Growth Catalyst Strategic integration with health tech and imaging AI players (Azra AI, CARPL.ai, RevealDx) and collaborations with academic and medical centers position Riverain as a growth-ready platform. Position ClearRead as a scalable backbone for AI-enabled thoracic imaging programs and care coordination workflows to attract large health systems.